KDIGO preferentially recommends the addition of a long-acting GLP-1 RA for glycemic control in patients with T2D and CKD who have not achieved individualized targets despite treatment with metformin and an SGLT-2i or those who are unable to tolerate these medications [18]. This evidence concerns the gene GLP1R and chronic kidney disease.